课题基金 / 基金详情

Exploiting Tumour Hypoxia in Precision Medicine: Advancing Novel Prodrug Therapies for Pancreatic Cancer with a World-leading Canadian Cancer Centre

Exploiting Tumour Hypoxia in Precision Medicine: Advancing Novel Prodrug Therapies for Pancreatic Cancer with a World-leading Canadian Cancer Centre
在精准医学中利用肿瘤缺氧:与世界领先的加拿大癌症中心共同推进胰腺癌的新型前药疗法
批准号:
132606
负责人:
金额:
$2.68万
依托单位:
依托单位国家:
英国
项目类别:
Feasibility Studies
财政年份:
2017
资助国家:
英国
项目状态:
已结题
起止时间:
2017 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
癌症治疗的有效性可能会受到肿瘤药物渗透障碍以及低氧或低氧肿瘤区域存在耐药细胞的限制--这些都成为扩散的来源。英国Oncotherics公司已经开发出无毒药物,旨在进入这些难以治疗的区域,感受低水平的氧气,并“激活”杀死有问题的癌细胞。胰腺癌的抗药性凸显了这一挑战,在英格兰和威尔士,每100名患者中只有1人能存活10年以上,而且自20世纪70年代以来几乎没有改善。我们的主要创新是与加拿大世界领先的癌症中心联系起来,进行临床试验,利用突破性的成像技术,使我们能够识别患有缺氧性肿瘤的胰腺癌患者,进行这种有针对性的药物治疗。融资将加速与PMCC的这种联系,随着进入一个17亿美元的全球市场,增加投资者兴趣的前景,为英国和全球的癌症中心提供一条获得监管批准和临床采用的途径。
英文摘要
The effectiveness of cancer therapy can be limited by barriers to drug penetration at the tumour and theharbouring of drug-resistant cells in poorly oxygenated or "hypoxic" tumour regions - these becomingsources of spread. The UK company Oncotherics has developed non-toxic drugs that are designed topenetrate into these difficult to treat regions, sense the low levels of oxygen and “activate” to kill theproblematic cancer cells. The challenge is highlighted by the treament resistance of pancreatic cancer withonly 1 in every 100 patients in England & Wales surviving their disease for more than 10 years with littleimprovment since the 1970s. Our key innovation is to link with a world-leading Cancer Centre in Canadato approach a clincal trial that exploits a ground-breaking imaging technology that will allow us to identifypancreatic cancer patients with hypoxic tumours for this targeted drug therapy. Funding will acceleratethis link with PMCC , increase the prospects for investor interest with entry into a $1.7bn global market,provide a route to regulatory approval and clinical adoption in cancer centres both in the UK & globally.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金